2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Opioids, Women’s Health, Adverse Events, Biological Processes, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Immunodeficiency, Infectious Diseases, Bacterial, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4693 Proteomic profile of osivelotor in patients with sickle cell disease in a multicenter phase 2/3 study: Improvements in inflammation and hemostatic balance

Kevin HM Kuo, MD, MSc, FRCPC, Pujan Joshi2, Wen He, N/A3, Shunjie Guan, N/A4, Craig Hyde, N/A5, Geoffrey Allen, MD6, Julie M Lee, N/A7, Santosh L Saraf, MD8, Kelly A Fader, PhD9
2 Pfizer Inc., Groton, Connecticut, United States
3 Pfizer Inc., Groton, Connecticut, United States
4 Pfizer Inc., Cambridge, Massachusetts, United States
5 Pfizer Inc., Groton, Connecticut, United States
6 Pfizer Inc., Collegeville, Pennsylvania, United States
7 Pfizer Inc., Cambridge, Massachusetts, United States
8 University of Illinois Chicago, Chicago, Illinois, United States
9 Pfizer Inc., Groton, Connecticut, United States

Introduction

Sickle cell disease (SCD) is characterized by the polymerization of sickle hemoglobin (HbS) leading to red blood cell (RBC) sickling, chronic hemolytic anemia, and chronic inflammation. The HbS polymerization inhibitor osivelotor is currently under evaluation for the treatment of SCD in an ongoing phase 2/3 trial (NCT05431088). In the 12-week, phase 2 portion of this trial, osivelotor was generally well tolerated in adults with SCD. Increases in Hb were observed following osivelotor treatment, with least-squares mean changes from baseline to Week 12 of +2.58 g/dL for the osivelotor 100 mg group and +3.35 g/dL for the osivelotor 150 mg group. Improvements in hematocrit, hemolysis biomarkers, scavenger proteins, RBC deformability, and flow adhesion were also reported in preliminary analyses. The aim of this analysis was to identify molecular pathways and biological functions modified by osivelotor. This analysis also evaluated the relationship between changes in molecular pathways and biological functions, and the pathological signature of SCD disease.

Methods

Exploratory data from the phase 2 portion of an ongoing multicenter, phase 2/3 trial (NCT05431088) were analyzed. The phase 2 portion was a randomized (1:1), open-label, 12-week, dose-finding study of osivelotor in adults with SCD (homozygous hemoglobin S genotype [HbSS] or compound heterozygous hemoglobin S/β0-thalassemia genotype [HbS/β0]) and a screening Hb of 5.5–10.5 g/dL. After providing consent, patients received loading doses twice-daily for 4 days, followed by 100 mg or 150 mg once-daily maintenance doses through Week 12. Plasma proteomic analysis was performed using the Olink® Explore high-throughput (HT) panel, which assessed approximately 5400 proteins (conducted at Olink®, Waltham, Massachusetts, USA). Functional enrichment analysis was conducted using Fast Gene Set Enrichment Analysis (fGSEA) with the Reactome database. Osivelotor-mediated changes were compared to a recently published proteomic dataset (Chignon A, et al. Blood Adv. 2026;10[10]:3420-3430) which assessed patients with SCD (HbSS; n = 376) relative to non-SCD controls (normal hemoglobin [HbAA] + sickle cell trait [HbAS]; n = 103), which also utilized the Olink Explore HT panel.

Results

Of the 3034 proteins which passed the assay-level QC, 972 biomarkers show a statistically significant change from baseline following osivelotor at one or more visits in at least one dose group (false discovery rate < 0.05). Functional enrichment analysis identified two key findings among the top 25 pathways modulated by osivelotor. Firstly, many immune-related pathways, including adaptive immune system, immunoregulatory interactions with lymphoid cells, neutrophil degranulation, infectious disease, and interferon signaling, generally decreased after osivelotor. Secondly, osivelotor has altered the expression of several hemostasis-related pathways closer to non-SCD controls, including the formation of fibrin clot, response to elevated platelet cytosolic calcium, platelet activation signaling and aggregation, and hemostasis. Comparison against the Chignon dataset revealed that most proteins elevated in SCD relative to non-SCD controls were reduced by osivelotor, while most proteins depleted in SCD increased after osivelotor. Specifically, osivelotor improved circulating levels of proteins involved in the immune response, inflammation, clot formation, and hemostasis, shifting the proteomic profile of the patients with SCD toward a healthy state.

Conclusions

Taken together, findings from this exploratory analysis from the phase 2 portion of this ongoing multicenter, phase 2/3 trial suggest that improvements in several pathological features of SCD, including chronic inflammation, immune dysregulation, and hemostatic imbalance, were observed following treatment with osivelotor. This is expected to reduce vasculopathy, organ damage, and the risk of acute SCD complications (such as vaso-occlusive crises, acute chest syndrome). Overall, these findings support the ongoing clinical development of osivelotor as a potential treatment for patients with SCD.

Clinicaltrials.gov NCT05431088

Kevin HM Kuo, MD, MSc, FRCPC: Biossil - Current holder of stock options in a privately-held company; Alexion Pharmaceuticals - Honoraria; Bristol Myers Squibb - Honoraria; Vertex Pharmaceuticals - Honoraria; Alexion Pharmaceuticals - Honoraria; Novo Nordisk - Honoraria; Novo Nordisk - Honoraria; Bristol Myers Squibb - Honoraria; Vertex Pharmaceuticals - Honoraria; Pfizer - Research Funding; Pfizer - Research Funding; Agios Pharmaceuticals, Inc. - Research Funding; Agios Pharmaceuticals - Research Funding; Alexion Pharmaceuticals - Consultancy (Includes expert testimony); Novo Nordisk - Consultancy (Includes expert testimony); DISC Medicine - Consultancy (Includes expert testimony); Alexion Pharmaceuticals - Consultancy (Includes expert testimony); Forma Therapeutics - Consultancy (Includes expert testimony); Agios Pharmaceuticals - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Vertex Pharmaceuticals - Consultancy (Includes expert testimony); Biossil - Consultancy (Includes expert testimony); Bristol Myers Squibb (Celgene) - Consultancy (Includes expert testimony); Bristol Myers Squibb (Celgene) - Consultancy (Includes expert testimony); Agios Pharmaceuticals, Inc. - Consultancy (Includes expert testimony); Biossil - Consultancy (Includes expert testimony); Novo Nordisk - Consultancy (Includes expert testimony); Vertex Pharmaceuticals - Consultancy (Includes expert testimony); Agios Pharmaceuticals, Inc. - Membership on a Board/Advisory Committee; Sangamo Therapeutics - Membership on a Board/Advisory Committee; Agios Pharmaceuticals - Membership on a Board/Advisory Committee; Sangamo Therapeutics - Membership on a Board/Advisory Committee